药明生物：首款药明双抗（WuXiBody）进入 Ⅲ 期临床试验

Fastest growing modality in 1H25: Of WuXi's 864 integrated projects in 1H25, 168 projects (or 19%) were bi-/multi-specific antibodies. Revenue from these contracts was up >200% YoY in 1H25, followed by ADCs (up 50% YoY). In addition to CD20/ CD3, WuXi's proprietary CD3 T-cell engager platform also engineered bi-/multi- specifics, such as CD3xCD19, CD3xPSMA, and CD3xCD19xCD20. TQB2825 has been tested in combination with immunochemotherapy and chemotherapy alone in two Phase 2 trials: TQB2825+R-CHOP (trial li ...